Unveiling 6 Analyst Insights On Intellia Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) vary from bullish to bearish, with recent ratings showing a mix of sentiments. The average 12-month price target has decreased by 8.16% to $63.0. Key analysts have maintained, raised, or lowered their ratings and price targets based on recent developments.
June 24, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia Therapeutics (NASDAQ:NTLA) has received mixed analyst ratings over the last quarter, with an average 12-month price target of $63.0, down 8.16% from the previous average. Key analysts have maintained, raised, or lowered their ratings and price targets based on recent developments.
The mixed analyst ratings and the decrease in the average 12-month price target suggest a neutral short-term impact on NTLA's stock price. While some analysts are bullish, others have lowered their ratings, indicating uncertainty in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100